Oric Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

ORIC Pharmaceuticals

12/03/2024 11:03

* Oric Pharmaceuticals Inc  ORIC.OQ   ORIC.O  is expected
to show
no change in quarterly revenue when it reports  results on May 6
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Oric Pharmaceuticals Inc
is
for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $15.00​, above​ its last closing price
of $14.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.49       -0.49      -0.49     Met     -0.7
 Sep. 30 2023  -0.46       -0.46      -0.44     Beat    4.7
 Jun. 30 2023  -0.57       -0.57      -0.50     Beat    12.1​
 Mar. 31 2023  -0.54       -0.54      -0.53     Beat    1.9
 ​​Dec.        -0.51       -0.54      -0.52     Beat    3
 31 2022                                                
 Sep. 30 2022  -0.55       -0.55      -0.63     Missed  -13.8​
 Jun. 30 2022  -0.61       -0.60      -0.51     Beat    15
 Mar. 31 2022  -0.56       -0.57      -0.59     Missed  -3.8
 This summary was machine generated March 12 at 11:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)